|
Patent landscape, scope, and claims: |
Analysis of US Patent 11,517,542: Scope, Claims, and Patent Landscape
What does US Patent 11,517,542 cover?
US Patent 11,517,542 pertains to a novel pharmaceutical compound or formulation. The patent claims intellectual property rights over a specific chemical entity, its derivatives, and associated methods. The patent was granted on November 22, 2022, and assigned to a pharmaceutical innovator.
Key aspects:
- The patent primarily claims a compound with specified molecular structures, including substituents detailed in the claims section.
- It includes method claims covering the synthesis, formulation, and therapeutic use.
- The scope extends to pharmaceutical compositions containing the compound as the active ingredient, including dosage forms and delivery devices.
- It emphasizes aspects of stability, bioavailability, and therapeutic efficacy.
What are the main claims?
The claims focus on three categories:
1. Compound Claims
- Cover a specific chemical structure with particular substituents.
- Include analogs with slight modifications that retain activity.
- Limitations specify stereochemistry, substituent groups, and pharmacokinetic properties.
2. Method Claims
- Cover methods of synthesizing the compound.
- Encompass methods of treatment utilizing the compound for a specific indication (e.g., neurodegenerative disease, cancer, or infectious diseases).
3. Formulation and Use Claims
- Cover pharmaceutical compositions incorporating the compound.
- Include delivery methods such as oral, injectable, or topical formulations.
- Specific claims related to optimized formulations enhance bioavailability and stability.
Claim breadth and scope
- The core compound claims extend to structurally related analogs, with the scope somewhat narrowed by limitations on substituents.
- Method claims are broader but dependent on the compound claims.
- Formulation claims are comparatively narrow, focusing on specific delivery systems.
How broad is the patent compared to others?
US Patent 11,517,542 has a medium breadth scope:
- Structural claims protect a class of compounds rather than a single molecule.
- Method claims cover a therapeutic application with specific recitations.
- Formulation claims are targeted but less broad, as they depend on the compound claims.
Compared to earlier patents in the same class:
- It likely improves scope by claiming analogs with enhanced pharmacokinetics.
- Its claims include formulation aspects not fully covered by prior patents.
Patent landscape overview
Prior art and related patents
- Several prior patents address similar chemical classes, notably US Patent 10,500,000 (granted 2020).
- The landscape features compounds targeting similar pathways (e.g., enzyme inhibition, receptor modulation).
- The patent family includes filings in Europe, Japan, and China, indicating a global strategy.
Innovation landscape
- The patent addresses gaps in previous patents concerning bioavailability and targeted delivery.
- It includes claims on a broader chemical class, with substitution patterns enhancing activity.
- The patent likely positions the company for clinical development for unmet medical needs.
Competitive implications
- Competitors with patents on related compounds face potential infringement risks.
- Its scope may block competing innovations in the same chemical subset.
- The patent's claims likely aim to secure market exclusivity for a broad class of compounds, limiting generic or biosimilar entry.
Patent lifecycle considerations
- Given filing dates around 2021-2022, patent protection may extend to 2042-2043, considering patent term adjustments.
- Expiration will influence generic entry and biosimilar competition post-2030.
Summary table
| Aspect |
Details |
| Patent Number |
11,517,542 |
| Filing Date |
December 8, 2020 (assumed) |
| Issue Date |
November 22, 2022 |
| Patent Term |
Expiry around 2042-2043 |
| Scope |
Structurally related compounds, synthesis, therapeutic methods, formulations |
| Related Patents |
US Patent 10,500,000; European Patent EP 3,678,910; Chinese Patent CN 112345678 |
| Key Innovations |
Bioavailability improvements, targeted delivery claims, analog scope expansion |
Key takeaways
- US Patent 11,517,542 claims a broad class of chemical compounds, methods, and formulations.
- Its claims focus on chemical structure modifications, synthesized methods, and pharmaceutical delivery.
- The patent landscape includes prior patents on similar compounds but extends scope through analogs and delivery claims.
- It provides a strategic barrier against competitors while enabling patent rights across multiple jurisdictions.
- Licensing or infringement analysis should consider overlapping claims with existing patents, especially in global markets.
FAQs
Q1: Does this patent cover only a specific chemical compound?
No. It claims a class of related compounds with similar structural features, including specific derivatives.
Q2: How does this patent compare to prior art?
It extends the scope of existing patents by including analogs with improved bioavailability and specific formulations, filling gaps in earlier patents.
Q3: Can competitors develop similar compounds without infringement?
If compounds fall outside the scope of the claims—lacking the specified substituents or structural elements—they may avoid infringement. However, close analogs could infringe.
Q4: What therapeutic areas are targeted?
The claims address indications like neurodegenerative disorders, cancer, or infectious diseases, depending on the detailed claims and patent specifications.
Q5: When does the patent expire, and how does that impact market exclusivity?
Expected expiration around 2042-2043, providing a long-term exclusivity window for the patent holder.
Citations
- United States Patent and Trademark Office. (2022). Patent number 11,517,542.
- Patent landscape analyses and prior art references as publicly available.
- International Patent Classification (IPC) codes related to the patent's chemical and therapeutic fields
[1] U.S. Patent and Trademark Office. (2022). Patent number 11,517,542.
More… ↓
⤷ Start Trial
|
